Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2065]
News [2970]
Articles [104]
Editorials [22]
Conferences [186]
elearning [62]
IDH metabolites induce a BRCAness that can be exploited by PARP inhibitors
Dr Ranjit Bindra - Yale School of Medicine, New Haven, USA
IDH metabolites induce a BRCAness that can be exploited by PARP inhibitors ( Dr Ranjit Bindra - Yale School of Medicine, New Haven, USA )
12 Apr 2017
Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker...
Prof Peter Schmid - Barts Cancer Institute, London, UK
Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker analyses ( Prof Peter Schmid - Barts Cancer Institute, London, UK )
11 Apr 2017
Five-year follow-up of nivolumab in NSCLC
Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
Five-year follow-up of nivolumab in NSCLC ( Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
11 Apr 2017
Mutations in cancer predisposition genes and risk for subsequent neoplasms
Dr Leslie Robison - St. Jude Children's Research Hospital, Memphis, USA
Mutations in cancer predisposition genes and risk for subsequent neoplasms ( Dr Leslie Robison - St. Jude Children's Research Hospital, Memphis, USA )
11 Apr 2017
Final overall survival analysis of MONARCH 1
Dr Hope Rugo - UCSF Medical Center, San Francisco, USA
Final overall survival analysis of MONARCH 1 ( Dr Hope Rugo - UCSF Medical Center, San Francisco, USA )
11 Apr 2017
Redefining tamoxifen for breast cancer
Gokul Das - Roswell Park Cancer Institute, Buffalo, USA
Redefining tamoxifen for breast cancer ( Gokul Das - Roswell Park Cancer Institute, Buffalo, USA )
11 Apr 2017
Olaparib and temozolomide for relapsed small cell lung cancer
Dr Anna Farago - Massachusetts General Hospital, Boston, USA
Olaparib and temozolomide for relapsed small cell lung cancer ( Dr Anna Farago - Massachusetts General Hospital, Boston, USA )
10 Apr 2017
Final results of the HERACLES trial in HER2-amplified colorectal cancer
Dr Silvia Marsoni - Candiolo Cancer Institute, Turin, Italy
Final results of the HERACLES trial in HER2-amplified colorectal cancer ( Dr Silvia Marsoni - Candiolo Cancer Institute, Turin, Italy )
10 Apr 2017
Treatment choices for HER2 amplified colorectal cancer
Dr Silvia Marsoni - Candiolo Cancer Institute, Turin, Italy
Treatment choices for HER2 amplified colorectal cancer ( Dr Silvia Marsoni - Candiolo Cancer Institute, Turin, Italy )
10 Apr 2017
Results of SUMMIT: a global phII trial of neratinib in HER2/3 mutant solid...
Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA
Results of SUMMIT: a global phII trial of neratinib in HER2/3 mutant solid tumours ( Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Apr 2017
Neratinib in HER2 or HER3 mutant solid tumours
Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA
Neratinib in HER2 or HER3 mutant solid tumours ( Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Apr 2017
Understanding response and resistance to cancer therapy: Lessons learned from...
Dr Jennifer Wargo - The University of Texas MD Anderson Cancer Center, Houston...
Understanding response and resistance to cancer therapy: Lessons learned from melanoma ( Dr Jennifer Wargo - The University of Texas MD Anderson Cancer Center, Houston, USA )
10 Apr 2017

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation